IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited (GKASSL) is a multispecialty health care service provider engaged in the provision of secondary and tertiary health care services in multiple locations across Gujarat, India. At the close of business on March 20, 2025, it operates six multispeciality hospitals and three pharmacies, representing a total bed capacity of 400 beds with an approved capacity of 355 beds and an operational capacity of 250 beds. The hospitals in the company include Gujarat Kidney and Super Speciality Hospital, Vadodara, Gujarat Multispeciality Hospital, Godhra, Raj Palmland Hospital Private Limited, Bharuch, M/s. Surya Hospital and ICU, Borsad, Gujarat Surgical Hospital, Vadodara, and Ashwini Medical Centre, Anand. It also holds a drugstore, Ashwini Medical Store, Anand. Services: Secondary Care Services: This refers to both general and surgical treatments. Tertiary Care Services: Super speciality surgical procedures. Gujarat Superspeciality Hospital provides medical care in the field of internal medicine, general surgery, minimally invasive procedures, orthopaedics and trauma treatment, joint replacement surgery, obstetrics and gynaecology, respiratory failure, non-interventional cardiology, diabetology, and anaesthesiology. At March 20, 2025, the company had 322 employees, which include 21 full-time Consultants and 32 visiting consultants. At September 30, 2024, the healthcare professionals of the company comprised 47 doctors and 138 nurses.
| Companies Name | Open - Close | Issue Size | Min. Qty | Issue Price | Apply |
|---|---|---|---|---|---|
IC Electricals Company SME | 3rd Jul 2026 - 7th Jul 2026 | 47.91 Cr | 1200 Shares | ₹ 94.00 |

Open Date
22 Dec 2025
Close Date
24 Dec 2025
Min Investment
₹14592
Lot Size
128 Shares
Issue Size
₹250.8 Cr
Price Range
₹108 - ₹114
Listing Date
Dec 30, 2025
IPO Doc
RHP PDFRevenue Growth
Company Valuation
Earning Expansion
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily.
The company will use ₹77 crore towards the proposed acquisition of Parekhs Hospital at Ahmedabad. ₹12.40 cr for part payment toward Ashwini Medical Centre. ₹10.78 cr to buy more stake in Harmony Medicare (Bharuch). The company will use ₹30.10 cr for Vadodara hospital & ₹6.82 cr for robotics. The company will use ₹1.20 crore towards repayment of certain outstanding borrowings
Funding for acquisition
30.7%
Part-payment for acquisition
4.94%
Investment in subsidiary
4.3%
Capital expenditure
14.72%
Repayment of borrowings
0.48%
The company will use ₹77 crore towards the proposed acquisition of Parekhs Hospital at Ahmedabad.
₹12.40 cr for part payment toward Ashwini Medical Centre.
₹10.78 cr to buy more stake in Harmony Medicare (Bharuch).
The company will use ₹30.10 cr for Vadodara hospital & ₹6.82 cr for robotics.
The company will use ₹1.20 crore towards repayment of certain outstanding borrowings
In Cr.
Revenue: ₹15.27
EBITDA: ₹8.63
Profit: ₹5.40
| Key Performance Indicator | 30-Jun-25 (In Cr.) | 31-Mar-25 (In Cr.) | 31-Mar-24 (In Cr.) | 31-Mar-23 (In Cr.) |
|---|---|---|---|---|
| Revenue | 15.27 | 40.40 | 5.48 | 0.00 |
| EBITDA | 8.63 | 16.55 | 1.95 | -0.01 |
| Expenses | ||||
| Profit After Tax | 5.40 | 9.50 | 1.71 | -0.01 |
| Assets | 61.59 | 55.34 | 20.53 | 3.87 |
| Net Worth | 30.56 | 25.71 | 10.80 | 0.37 |
| Reserves | 19.42 | 14.57 | 10.60 | 0.17 |
| Borrowing | 4.03 | 3.88 | 1.94 |
Dr. Pragnesh Yashwantsinh Bharpoda
Dr. Bhartiben Pragnesh Bharpoda
Dr. Yashwantsingh Motisinh Bharpoda
Anitaben Yashwantsinh Bharpoda
99.10%
71.45%
Gujarat Kidney & Super Speciality
Plot No. 1, City Sarve No. 1537/A, Jetalpur Road, Gokak Mill Compound, Alkapuri, Vadodara, Gujarat, India Vadodara, Gujarat, 390020
MUFG Intime India Pvt.Ltd.
The company is very successful in attracting talent and keeping them as employees, and thus it has a very low turnover rate. The turnover of full-time doctors in FY25 and Q1 FY26 was between 2.40% and 2.99%, while the turnover rate of visiting doctors and nurses was close to zero. As of June 30, 2025, the company has 89 doctors and over 330 nurses, who were supported by well-organised engagement models and continuous medical education programs.
The main source of revenue is the demand for services by patients. A huge 94.54% in Q1FY26 and 90% in FY25 were from individual patients with insurance and walk-ins. Besides that, participation in Ayushman Bharat and corporate empanelments offers additional volumes without compromising price discipline.
A major part of their revenue is geographically concentrated in Central Gujarat, with 40.32% revenue contribution from Central Gujarat, 18.40% from North Gujarat, and 41.28% from South Gujarat in FY25. A major disruption in these regions can affect their performance.
The majority of the company’s major hospitals are functionally leased and have leased terms varying from 11 months to 15 years. The cost of these lease agreements contributed 3.71% of total expenses in Q1FY26 and 3.36% in FY25. A situation where such properties are not renewed or, in case of a dispute/termination, especially where they belong to promoters, can affect operations.